ABSTRACT

Introduction: The present paper focuses on the possible contribution of food compounds to alleviate symptomatic pains. Chronic pain can more easily be linked to anticipatory signals such as thirst and hunger than it is to sensory perceptions as its chronicity makes it fall under the behavioural category rather than it does senses. In fact, pain often negatively affects one's normal feeding behavioural patterns, both directly and indirectly, as it is associated with pain or because of its prostrating effects.

Nutritional Compounds for Pain: Several nutraceuticals and Foods for Special Medical Purposes (FSMPs) are reported to have significant pain relief efficacy with multiple antioxidant and anti-inflammatory properties. Apart from the aforementioned properties, amino acids, fatty acids, trace elements and vitamins may have a role in the modulation of pain signals to and within the nervous system.

Conclusion: In our opinion, this review could be of great interest to clinicians, as it offers a complementary perspective in the management of pain. Trials with well-defined patient and symptoms selection and a robust pharmacological design are pivotal points to let these promising compounds become better accepted by the medical community.

Keywords: Amino acids (tryptophan; phenylalanine; carnitine); Fatty acids (resolvines; PEA); Food for pain; Food for medical purposes; Magnesium; Metalloporphyrins; Selenium; Vitamins
**Key Summary Points**

Nutraceuticals are products isolated or purified from foods and generally are sold in medicinal form as a supplement rather than as a food. This definition encompasses a wide range of compounds: vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandular materials, and metabolites.

Foods for Special Medical Purposes (FSMPs) are a new class of therapeutics, which can be used under medical control to cure diseases and alleviate symptoms.

Emerging literature suggests that diet constituents may play a modulatory role in chronic pain through management of inflammation/oxidative stress, resulting in attenuation of pain.

Nutraceuticals and FSMPs may have some role in the modulation of pain signals to and within the nervous system.

Very few randomised controlled trials in humans are present in the literature and, as such, the current situation does not allow us to fully support the use of nutraceuticals and FSMPs on a broader basis.

**DIGITAL FEATURES**

This article is published with digital features, including a summary slide to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13664294.

**INTRODUCTION**

Chronic pain can more easily be linked to anticipatory signals such as thirst and hunger than it is to sensory perceptions as its chronicity makes it fall under the behavioural category rather than it does senses [1]. Pain and eating are two complex behaviours that are strictly correlated on a neurological level. In the occurrence of ill health, pain actively limits the normal dietary behaviour in an individual both directly and indirectly, due to physical suffering and fatigue. Moreover, in the occurrence of an eating disorder such as anorexia nervosa, pain and hunger are believed to be affected even without a neurological impairment [2]. On the other hand, obesity has also been evaluated as a possible marker for increased pain severity and it has been related to obesity in postmenopausal woman [3, 4]. When analysing chronic pain on a psychosocial level, these two opposite clinical pictures are a strong example of the correlation between pain and food. In fact, it is not the food itself but some of its natural compounds that may work as a trigger. In this field, the majority of reports claiming a beneficial use of food to control a series of signs and symptoms seem to be just anecdotal [5].

A search of the medical literature with Medical Subject Headings (MeSH) “nutraceuticals” combined with “pain relief” affords a list of about 1,900,000 websites with “nutraceuticals” for pain relief. Nutraceuticals are products isolated or purified from foods and generally sold in medicinal form as a supplement rather than as a food. This definition encompasses a wide range of compounds: vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandular materials, and metabolites. Dietary supplements can also be extracts or concentrates. This broad group of compounds was demonstrated to have a physiological benefit or provide protection against chronic diseases, such as osteoarthritis (OA), muscle pain and headaches [6, 7]. However, nutraceuticals have issues not only in Europe but also worldwide with accuracy of dose, preparation and consistent pharmacodynamics.

Moreover, in recent years in Europe, the USA and Japan a new class of therapeutics has been introduced, which can be used under medical control to cure diseases and alleviate symptoms. These are labelled as Foods for Special Medical
Purposes (FSMPs) [8]. The European Commission Directive on dietary Foods for Special Medical Purposes (Directive 2006/141/EC) sets out rules for the composition and labelling of foods that are specifically formulated, processed and intended for the dietary management of diseases, disorders or medical conditions of individuals who are being treated under medical supervision [9]. These foods are intended for the exclusive or partial feeding of people with specific nutritional requirements. In other words, nutraceuticals are intended to eventually reduce the risk of diseases while FSMPs are labelled as medicines for therapeutic use under medical control.

This manuscript aims to analyse the most relevant compounds researched in peer-reviewed journals from well-known databases like PubMed, EMBASE, Medline and Google Scholar. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

NUTRITIONAL COMPOUNDS FOR PAIN

Antioxidant Properties

Excessive eating and drinking habits have been associated with increased oxidative stress and indirectly related to pain generation and maintenance. The nervous system, and particularly the brain, is vulnerable to oxidative damage [10] and it can affect the development of different neurodegenerative disorders including Alzheimer's disease [11], Parkinson's disease [12] and amyotrophic lateral sclerosis [13]. This mechanism can be of some importance in the occurrence of pervasive pain as an onset symptom in the early stage of dementia [11].

In the last decade, there have been major improvements in understanding the mechanisms underlying the transition of acute to chronic pain, the formation and exacerbation of neuropathic pain, and the development of opioid-induced tolerance and hyperalgesia especially when looking at the role of oxidative stress agents such as peroxynitrite (PN) and its reactive oxygen precursor superoxide (SO) [14]. This has led to a promising treatment strategy, namely the use of antioxidant compounds or scavengers against PN and SO to reduce oxidative stress and prevent the establishment of favourable conditions for the transition towards chronic pain states as in the management of musculoskeletal disorders in the elderly where multiple pharmacological treatments are already present [15, 16].

Anti-Inflammatory Properties

A diet rich of refined starches, sugar, saturated and trans-fats can promote inflammation [17]. In the Nurses’ Health Study, women with a diet based on refined grains, had high levels of C-reactive protein, interleukin-6 (IL-6), E-selectin, soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1) [18]. A direct relationship between trans-fatty acid consumption and higher inflammatory markers such as IL-6 was also observed [19]. This has been confirmed across a number of controlled trials and observational studies [20] and recently reviewed [21].

The existing literature is very thorough on the role of nutraceuticals with a declared antioxidant anti-inflammatory activity [6, 22, 23] such as curcumin [6], resveratrol [24] and omega-3 polyunsaturated fatty acid [25]. The combination of curcumin and resveratrol can induce a significant inhibition of tumour necrosis factor-alpha (TNFα) and nitric oxide (NO) levels in painful diabetic polyneuropathy in humans [26], to attenuate thermal hyperalgesia in animals and to interfere with morphine tolerance [27]. Curcumin has been shown to provide some help in alleviating pain of different origin [6] showing effects equivalent to ibuprofen and diclofenac, without the adverse effects generally reported by patients [28].

Amino Acids

Amino acids are nitrogen-containing molecules critically necessary for the production of proteins. They can be widely found in many foods, including meat, eggs, milk, fish, plants and...
nuts. They are utilised for the production and function of almost every tissue in the body, especially involving the musculoskeletal system [29]. As such they might be able to provide pain relief via accelerating tissue-healing mechanisms induced by an anabolic activity. Indeed, a mixture of essential amino acids improves pain of elderly subjects following elective surgery for hip OA within 2 weeks after operation [30]. Tryptophan, L-phenylalanine and carnitine are of particular interest (Table 1).

Tryptophan
One of the most remarkable compounds in the treatment of chronic pain is tryptophan, an amino acid precursor of 5-OH-tryptamine or serotonin, a neurotransmitter involved with noradrenaline in pain control descending systems [31]. Its use alone or in combination with a selective serotonin reuptake inhibitor (SSRI) can help in controlling the pain or in reducing the use of SSRI antidepressants on the basis of the assumption that many pain states are determined by a decreased efficiency of the serotonergic descending system and that increased supplementation along with a blockade of its elimination can lead to increased control of pain [32, 33]. Indeed, in generalized pain states in which fatigue, mood changes and diffuse pain occur, such as fibromyalgia and irritable bowel syndrome, an abnormal engagement of descending mechanisms with or without reduced inhibition has been suggested [34, 35]. However, the balance between descending controls, both excitatory and inhibitory, seems to be more important than a simple reduction of one component [33]. Unfortunately, tryptophan is available in vegetables only in small quantity and to achieve a therapeutic daily intake it is necessary to supplement dietary intake with tablets.

Phenylalanine
Phenylalanine, widely known for its use in the treatment of phenylketonuria, is another agent with a potential contribution in the management of chronic pain. Phenylalanine is presumed to act as an enkephalinase inhibitor and thus increases the release of enkephalins in the dorsal horns and to potentiate endogenous opioid activity [35]. According to clinical observation, co-administration of opioids and phenylalanine in cases of drug dependence required lower levels of opiates [36], supporting phenylalanine’s property in increasing opioid activity. Seeds, nuts, almonds and soybeans are rich sources of phenylalanine and except for medical disorders its deficiency is less expected.

Carnitine
The amino acid carnitine is related to the proper functioning of almost all systems in the human body. Carnitine deficiency is characterized by various metabolic, cardiological and musculoskeletal problems, which vary widely in age of onset and presentation [37]. Carnitine has a potential neuroprotective role in many neurological disorders [38] enriched by the assumption that carnitine has an effect on pain reduction. According to a recent study in patients with mild to moderate carpal tunnel syndrome, the possible neuroprotective effect of carnitine relies on the improvement of mitochondrial function [39, 40]. Pain reduction is possibly achieved by the dysregulation of glutamate in the dorsal horns, via carnitine-induced activation of metabotropic glutamate receptor 2 (mGluR2) [41]. Preliminary data also suggest that metabolic pathways regarding L-carnitine synthesis may play a role in pain severity and interference in women with fibromyalgia; however, further investigation is necessary to confirm this hypothesis [42]. Carnitine can be widely found in meat and dairy products; carnitine deficiency is very rare and only due to pathological conditions.

Fatty Acids
Fatty acids of particular interest are summarised in Table 1.

Omega-3 Polyunsaturated Fatty Acids: Resolvines
Omega-3 polyunsaturated fatty acids include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and are present in dietary essential fat especially in fish. DHA and EPA are
Table 1 References for amino and fatty acids and trace elements cited in the text are herein reported

| Amino acids          | Reference | First author | Year |
|----------------------|-----------|--------------|------|
| Tryptophan           | [31]      | Baldin       | 2011 |
|                      | [32]      | Saarto       | 2007 |
|                      | [34]      | Bannister    | 2009 |
|                      | [35]      | Russell      | 2000 |
| L-Phenylalanine      | [35]      | Russell      | 2000 |
|                      | [36]      | Chen         | 2004 |
| Carnitine            | [37]      | Magoulas     | 2012 |
|                      | [38]      | Maldonado    | 2020 |
|                      | [39]      | DiCesare Mannelli | 2007 |
|                      | [40]      | Chierchio    | 2007 |
|                      | [41]      | Cruccu       | 2017 |
|                      | [42]      | Menzies      | 2020 |
| Fatty acids          |           |              |      |
| Ω-3 Polyunsaturated acids: resolvines | [43]      | Ji           | 2011 |
|                      | [44]      | Okubio       | 2010 |
|                      | [45]      | Seki         | 2009 |
|                      | [46]      | Serhan       | 2015 |
|                      | [47]      | Tokuyama     | 2011 |
|                      | [48]      | Prego-Dominguez | 2016 |
|                      | [52]      | Figueroa     | 2013 |
|                      | [130]     | Russo        | 2018 |
precursors of a new family of pro-resolving mediators of inflammation called resolvines. Resolvines can dampen pain via multiple mechanisms reducing inflammatory factors, the glia and the spinal cord synaptic plasticity [43]. It is very interesting to note that resolvines are strongly induced not only in the periphery during acute inflammation but also in the

Table 1 continued

| Reference | First author | Year |
|-----------|--------------|------|
| [49]      | Lambert      | 2002 |
| [50]      | Truini       | 2011 |
| [51]      | Skaper       | 2015 |
| [53]      | Costa        | 2008 |
| [54]      | Aldossary    | 2019 |
| [55]      | Conigliaro   | 2011 |
| [56]      | Scaturro     | 2020 |
| [57]      | Del Giorno   | 2015 |
| [58]      | Alshelh      | 2019 |
| [59]      | Marini       | 2012 |
| [60]      | Gugliandolo  | 2020 |
| [61]      | Paladini     | 2016 |
| [62]      | Medina-Cruz  | 2018 |
| [63]      | Kieliszek    | 2017 |
| [64]      | Reinhard     | 1998 |
| [65]      | Yüksel       | 2017 |
| [66]      | Sousa        | 2018 |
| [67]      | Welch        | 2017 |
| [68]      | Rondón       | 2010 |
| [69]      | Sun          | 2017 |
| [70]      | Banerjee     | 2017 |
| [71]      | Oh           | 2019 |
| [72]      | Park         | 2020 |
| [73]      | Tarleton     | 2020 |
| [74]      | Rausaria     | 2011 |
| [75]      | Li           | 2008 |
dorsal root ganglia and spinal cord [44]. Even if resolvines can be seen as a novel and extremely interesting approach both to prevent and cure pain associated with inflammation control, they are metabolically unstable in that they are rapidly inactivated in vivo, thereby reducing their possible utilization. A novel and more stable form of resolvines has been under study [45].

High serum concentration of omega-3 polyunsaturated fatty acids is associated with anti-nociception and lower levels of inflammatory mediators [46]. Dietary supplementation has shown reduction of pain related to rheumatoid arthritis, inflammatory bowel disease, neuropathy and dysmenorrhoea [47], with the largest effect on dysmenorrhoea according to recent a systematic review and meta-analysis [48].

**N-Palmitoylethanolamide (PEA)**

N-Palmitoylethanolamide (PEA) is a shorter and fully saturated analogue of anandamide [49]. PEA is a natural compound from soybean lecithin, egg yolk and peanut meal. PEA is accumulated during inflammation and has a number of anti-inflammatory effects, including effects in clinically relevant animal models of inflammatory as well as neuropathic pain. PEA is produced during inflammation and it was proposed that PEA acts as an “ALLAmide” (autacoid local inflammation antagonist amide) via its action on mastocytes, a pivotal cell in the inflammatory process. Moderation of mast cell activity has been suggested to contribute to the reduction of endoneurial edema, relieving conduction blocks in electromyographic studies in patients with chemotherapy-induced painful neuropathy [50]. PEA modulates local cells, degranulation and the reduction in the production of many inflammatory mediators such as TNFα and neurotrophic factors like nerve growth factor (NGF) [49, 51].

Furthermore, metabolic products related to N-acetylenolamine metabolic pathways of omega-3 polyunsaturated fatty acids seem to present antihyperalgesic effects, mediated by reduction of painful biomarkers in the spinal cord [52]. PEA also shows a direct action on pain mechanisms. In a model of neuropathic pain in animals (chronic constriction injury of the sciatic nerve), PEA was able to reduce both thermal hyperalgesia and mechanical allodynia [53]. Its mechanisms of action are mediated by the cannabinoid (CB1) and transient vanilloid (TRPV1) receptors, suggesting that the most likely antinociceptive mechanism might be the so-called entourage effect due to the PEA-induced inhibition of the enzyme catalysing the endocannabinoid anandamide (AEA) degradation [51, 54]. These data have been clinically confirmed in humans with neuropathic compression pain [55], in subjects with chronic low back pain [56, 57], in fibromyalgia [58], in nociceptive pain due to temporomandibular joint arthritis [59] and confirmed in pooled meta-analysis data in both chronic and neuropathic pain associated with neuroinflammation [60].

In addition PEA is thought to play a role as a glial modulator by targeting alpha peroxisome proliferator-activated receptors (PPARα), expressed on neurons and astrocytes, pain mediators which are activated as a response to nerve damage. Recent evidence suggests a reduction in oscillatory activity along the ascending pain pathway for patients with chronic neuropathic pain [61].

**Trace Elements**

Trace elements of particular interest are summarised in Table 1.

**Selenium (Se)**

Selenium (Se) can be found in Brazilian nuts, fish, meat and eggs and, in addition to its antioxidant properties, regenerates vitamins C and E and boosts the immune system’s function by improving its ability to fight infections and cancer cells [62, 63]. Regarding pain syndromes, lower Se levels have been found in cases of chronic pain conditions and especially in patients with fibromyalgia [64]. In an animal experiment in which a fibromyalgia-like syndrome was provoked, low dose of supplementation with Se was associated with a decrease in the fibromyalgia-induced hyperalgesia, reactive oxygen species (ROS), apoptosis and Ca²⁺ entry.
Interestingly this last effect was mediated through transient receptor potential melastatin 2 (TRPM2) and transient receptor potential vanilloid 1 (TRPV1) in the sciatic nerve and the dorsal root ganglion, suggesting the utilization of Se in clinical practice as a complement in the treatment of fibromyalgia [65]. Additionally $\alpha$-(phenylselanyl)acetophenone, an organic compound of selenium, demonstrates antioxidant, antidepressant and antinociceptive activities in animal models, possibly by intervening in monoamine oxidase (MAO-A) inhibition [66].

**Magnesium (Mg)**
Wholegrain bread, brown rice, nuts, green leafy vegetables, fish, meat and dairy products are rich sources of Mg. A deficiency in the essential mineral Mg can result in painful muscle cramps. Thus, it is inferred that a Mg intake will reduce muscle pain and produce muscle relaxation in all conditions [67]. However recent studies suggest that Mg has a much more direct involvement in the amelioration of pain. Experiments in rats with induced diabetic neuropathy showed that per os administration of Mg abolished thermal and tactile allodynia, decreased the development of mechanical hypersensitivity, and reduced N-methyl-D-aspartate receptor (NMDA) sensitivity in the spinal cord [68]. This finding was reaffirmed quite recently, as intrathecal sulfate application of Mg in rats proved to attenuate remifentanil-induced postoperative hyperalgesia again by downregulating the NMDA receptor activity in the spinal cord [69]. Thus Mg-mediated blockade of NMDA receptors can be a promising new therapeutic option for the management of chronic pain conditions, even especially when central pathways are involved. Clinical application up to now regards efficacy of Mg administration in cases of migraine [70], postoperative chronic knee pain [71] and chronic pain [70, 72, 73].

**Iron (Fe) and Manganese (Mn)**
Metalloporphyrin complexes with Fe and Mn have been identified as possible therapeutic agents as they show potent action in a model of carrageenan-induced thermal hyperalgesia and mechano-allodynia in a model of chronic neuropathic pain in animals [74]. Manganese deficiency is very rare in humans. The very limited evidence in humans suggests that Mn deficiency might cause bone demineralization and altered mood and increased premenstrual pain in women [75]. As far as we know there are no data on their efficacy in humans even if it is common sense that vitamins and minerals are essential for a balanced diet now encompassed under the label of nutraceuticals.

**Vitamins**
Vitamins of particular interest are summarised in Table 2.

**Vitamin B**
Vitamin B complex has multiple roles in the production and function of multiple cells within the body and also displays antioxidant actions. A diet with wholegrain bread, rice, cereals, fruits, peas, broccoli, eggs, liver, kidneys, chicken, meat and dairy products provides sources of all subgroup substances of vitamin B complex [76]. The role of subgroups of vitamin B complex as an adjuvant in causing analgesia is quite controversial. It seems that vitamin B as a supplement itself is not able to produce a strong analgesic effect, but it contributes and synergistically enhances the action of anti-inflammatory agents in both humans and animals [77–80].

Investigations in chemical and thermal models of nociception in mice suggested that the antinociceptive effect of some vitamin B groups may involve inhibition of the synthesis and/or action of inflammatory mediators [81]. However, a more direct analgesic and possible neuroprotective role of vitamin B complex has been also described in recent research studies in animals, implicating either the activation of astrocytes and microglial cells and increase in synthesis of $\gamma$-aminobutyric acid (GABA) [82] or the modulation of TRPV1 [83] as possible underlying pathophysiological mechanisms. A combination containing vitamin B has been
Table 2 References for vitamins (B; C; D and K; E) cited in the text are herein reported

| Vitamins | Reference | First author | Year |
|----------|-----------|--------------|------|
| Vitamin B | [76]      | Ang          | 2008 |
|          | [77]      | Kuhlwein     | 1990 |
|          | [78]      | Reyes-Garcia | 1999 |
|          | [79]      | Levin        | 2009 |
|          | [80]      | Caram-Salas  | 2004 |
|          | [81]      | França       | 2001 |
|          | [82]      | Yu           | 2013 |
|          | [83]      | Kopruszinski | 2015 |
|          | [84]      | Jhun         | 2020 |
| Vitamin C | [85]      | Undurti      | 2001 |
|          | [86]      | Fain         | 2005 |
|          | [87]      | Dionne       | 2016 |
|          | [88]      | Ekrol        | 2014 |
|          | [89]      | Kim          | 2016 |
|          | [90]      | Carr         | 2014 |
|          | [91]      | Zeraati      | 2014 |
|          | [92]      | Mikirova     | 2012 |
|          | [93]      | Carr         | 2017 |
| Vitamins          | Reference | First author     | Year |
|-------------------|-----------|------------------|------|
| Vitamins D and K  | [95]      | Jansen           | 2013 |
|                   | [96]      | Bhan             | 2010 |
|                   | [97]      | McCarthy         | 2015 |
|                   | [98]      | Shinchuk         | 2007 |
|                   | [99]      | Matossian-Motley | 2016 |
|                   | [100]     | Shipton          | 2015 |
|                   | [101]     | Waikakul         | 2012 |
|                   | [102]     | Lee              | 2008 |
|                   | [103]     | Jesus            | 2013 |
|                   | [104]     | Laslett          | 2014 |
|                   | [105]     | Haque            | 2010 |
|                   | [106]     | Huang            | 2013 |
|                   | [107]     | Wepner           | 2014 |
|                   | [108]     | Diao             | 2017 |
|                   | [109]     | McAlindon        | 2013 |
|                   | [110]     | Heldt-Frankling  | 2017 |
|                   | [111]     | Kalueff          | 2007 |
|                   | [112]     | Garcia           | 2002 |
|                   | [113]     | Heldt-Frankling  | 2017 |
|                   | [114]     | Cury             | 2011 |
|                   | [115]     | Ambrozetwicz     | 2019 |
|                   | [116]     | Lanham-New       | 2008 |
| Vitamin E         | [117]     | Packer           | 1991 |
|                   | [118]     | Edmondson        | 1997 |
|                   | [119]     | Blankenhorn      | 1986 |
|                   | [120]     | Ziaei            | 2005 |
|                   | [121]     | Shobei           | 2014 |
|                   | [122]     | Argyriou         | 2006 |
|                   | [123]     | Wadleigh         | 1992 |
|                   | [124]     | Kim              | 2006 |
shown to ameliorate the progression of osteoarthritis in humans [84].

**Vitamin C**

Vitamin C is an additional nutrient ingredient, present in oranges, strawberries, broccoli, peppers and potatoes. It is considered a strong antioxidant agent with multiple physiologic and metabolic effects [85]. Vitamin C deficiency has been directly associated with general musculoskeletal pain [86], spinal neck and low back pain, arthritis and rheumatism [87]. Furthermore, according to several studies, vitamin C supplementation on a daily basis helps in preventing the development of complex regional pain syndromes (CRPS) [88], might ameliorate pain symptoms in post-herpetic and cancer-related pain [89, 90] and decreases the dose of opioid consumption in experiments with mice [91].

Despite its multiple contributions in clinical pain reduction, the exact pathophysiological mechanism of vitamin C is more speculated than known. Vitamin C has anti-inflammatory properties by means of decreasing markers of inflammation in blood circulation [92], perhaps via its antioxidant mediation. This feature might contribute to a more general analgesic effect. However, vitamin C is a crucial cofactor for the production of serotonin, noradrenaline and endorphins involved in pain neuromodulation. As such, recent evidence suggests that these mechanisms are potential additional contributors to the analgesic effect exhibited by vitamin C [93].

**Vitamins D and K**

Vitamin D can be found in oily fish, red meat, liver, egg yolks and cereals. Additionally, the body makes good use of vitamin D, which comes from the sun or from a supplement, to build stronger bones. Poor vitamin D status frequently occurs in the general population and even more in disease states for two main reasons: low exposure to the sun and lack of vitamin D intake [94].

Lack of vitamin D is clearly associated with pain due to pathological skeletal conditions such as osteoporosis [95] and osteomalacia [96]. Moreover, as vitamin D also contributes to correct functioning of muscle, studies also showed that low serum levels of vitamin D are linked to muscle cramping and menstrual pain [97]. Poor body vitamin D status may represent an important risk factor for development and/or maintenance of both acute and chronic pain in various nonspecific musculoskeletal pain [98].

More recent evidence suggests that deficiency of vitamin D is linked to a higher prevalence of musculoskeletal pain [99], chronic pain [100], failed back surgery syndrome (FBSS) [101], neuropathic pain [102], fibromyalgia [103], OA [104] and rheumatoid arthritis [105]. On the other hand, supplementation of vitamin D has been found to improve pain in ambulatory subjects with nonspecific musculoskeletal pain [106], fibromyalgia [107], knee OA [108, 109] and in palliative care [110].

As a neuroactive steroid, vitamin D modulates the sensitivity of both neurotransmitters and relevant receptors as well as the signal transduction of pain, in the brain and the periphery [111]. It possesses a neuroprotective role by upregulating neurotrophins [112] and perhaps contributes to pain relief via various anti-inflammatory actions such as inhibition of cyclooxygenase-2 (COX-2), upregulation of prostaglandins and downregulation of inflammatory cytokines and excessive T lymphocyte infiltration [113]. An additional antinociceptive feature concerns the inhibition of NO, which moreover contributes to the development of central sensitization [114].

Furthermore, the combined use of vitamins D and K2 may protect redox balance and support the growth of osteoblasts [115] and thus further contribute to pain control in osteoporotic bone [116].

**Vitamin E**

Vitamin E is an additional important antioxidant agent and is found in plant oils like soya, corn and olive oil, in cereal products and in nuts and seeds. It helps to avoid the damage caused to the body by free radicals, protecting cell membranes from peroxidative stress [117]. Vitamin E exerts an analgesic effect in several pathologies such as rheumatoid arthritis [118], OA [119], dysmenorrhoea [120], premenstrual...
syndrome [121] and chemotherapy-induced conditions [122, 123]. Interesting laboratory findings suggested that the analgesic actions of injected vitamin E were mediated through depressing the NMDA receptor activity in dorsal horns [124]. However, as vitamin E is very far from a first-line pain-relieving option, there is a lack of recent evidence for its role in pain modulation.

A summary of all compounds reviewed is reported in Tables 1 and 2.

Psychophysical Influence on Food Choice and Related Consequences

To underline the importance of the biopsychosocial model to understand the development of chronic pain syndromes and the possible role of food, it is worth noting that stress and depression can influence food choices, enhancing maladaptive metabolic responses to unhealthy meals [125]. Combination of stressor events and incongruous diet can affect mood as well as further pro-inflammatory responses to stressors with the production of cytokines also in the absence of infection or injury [126].

Indeed depression and stressful events motivate less healthy food choices with greater risk related to being female and already overweight [3, 4]. Female college students in East European countries reporting a perceived stress ate more sweets and fast foods than those less stressed. Also men modify their dietary habits in relation to psychological distress, decreasing their vegetable intake following divorce or bereavement, but then increasing vegetable consumption after remarrying. Thus, in general, depression, stress and stressful pain conditions promote less healthy food choices that can boost increased oxidative stress and inflammatory responses that can open the gate to chronic painful states.

CONCLUSION

Emerging literature suggests that diet constituents may play a modulatory role in chronic pain through management of inflammation/oxidative stress, resulting in attenuation of pain. However the diet in general is only one part of the complex rehabilitation approach of patients with chronic pain and that they should not be considered a quick-fix pill.

Two aspects come out from the critical review on nutraceuticals and FSMPs; a considerable bulk of evidence came from the basic science strongly suggesting that almost all the cited food compounds may have some role in the modulation of pain signals to and within the nervous system. Moreover, recent advances in research have described the importance of the microbiota–gut–brain axis in influencing normal physiology and contributing to disease [127]. Indeed there is evidence that microbiota which is highly influenced by food intake may have an important role also in the perception of pain [128–130]. However, on the other hand very few randomised controlled trials sufficiently well designed to reach evidence-based medicine grade A and grade B are present in the literature on humans. As such, the current situation does not allow us to fully support the use of nutraceuticals and FSMPs on a broader basis. Thus, a warning should be made about the efficacy of nutraceuticals to control pain because of the ubiquitous presence of placebo effects. Indeed, placebo effects still retain an ambiguous and unsettling presence in biomedicine [131], especially regarding pain and in areas where placebo-controlled studies are lacking. Further, a number of these agents thought to perform amazing and revitalizing effects are much more ambiguous in their analgesic efficacy. Several reasons can be claimed for this apparent scotoma of all this possible contribution to pain control. Indeed, the most important of these is the already cited lack of clinical data. Trials with well-defined patient and symptoms selection and a robust pharmacological design are pivotal to letting these promising compounds become accepted by the medical community. It goes without saying that as “pain” is much more related to thirst and hunger than other sensations, eating habits and the presence of special food compounds must be considered with more attention by all the medical stakeholders involved in pain medicine.
ACKNOWLEDGEMENTS

The authors wish to thank Prof Roberto Aquilani (MD) for his supervision of the vitamin D section.

Funding. No funding or sponsorship was received for this study or publication and the Rapid Service Fee of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contribution. Authors made substantial and equal contributions to the conception and design of the article, and in drafting and revising it critically.

Disclosures. The authors Roberto Casale, Zaira Symeonidou, Sofia Ferfeli, Fabrizio Micheli, Paolo Scarsella, Antonella Paladini declare they have nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Wall PD. On the relation of injury to pain. The John J Bonica lecture. Pain. 1979;6(3):253–64.
2. Goldzak-Kunik G, Friedman R, Spitz M, Sandler L, Leshem M. Intact sensory function in anorexia nervosa. Am J Clin Nutr. 2012;95(2):272–82.
3. Marcus DA. Obesity and the impact of chronic pain. Clin J Pain. 2004;20(3):186–91.
4. Braden JB, Young A, Sullivan MD, Walitt B, Lacroix AZ, Martin L. Recurrent pain conditions in the women’s health initiative observational cohort. J Pain. 2012;13(1):64–72.
5. Health Canada. Nutrition recommendations: the report of the Scientific Review Committee. Ottawa: Supply and Services Canada; 1990.
6. Olsen NJ. Nutraceuticals for the treatment of osteoarthritis. Minerva Med. 2011;102(1):33–40.
7. Taylor FR. Nutraceuticals and headache: the biological basis. Headache. 2011;51(3):484–501.
8. Foods for Special Medical Purposes. https://ec.europa.eu/food/safety/labelling_nutrition/special_groups_food/medical_en. Accessed 2009.
9. Dietary Foods for Special Medical Purposes. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISLUM:l21101c. Accessed 2011.
10. Macri MA, D’Alessandro N, Di Giulio C, et al. Region-specific effects on brain metabolites of hypoxia and hyperoxia overlaid on cerebral ischemia in young and old rats: a quantitative proton magnetic resonance spectroscopy study. J Biomed Sci. 2010;17:14.
11. Seneff S, Wainwright G, Mascitelli L. Nutrition and Alzheimer’s disease: the detrimental role of a high carbohydrate diet. Eur J Intern Med. 2011;22(2):134–40.
12. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol. 2003;53(Suppl 3):S26-36.
13. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 1995;56(14):1151–71.

14. Salvemini D, Neumann W. Targeting peroxynitrite driven nitroxidative stress with synzymes: a novel therapeutic approach in chronic pain management. Life Sci. 2010;86:604–14.

15. Perna S, Alalwan TA, Al-Thawadi S, et al. Evidence-based role of nutrients and antioxidants for chronic pain management in musculoskeletal frailty and sarcopenia in aging. Geriatrics (Basel). 2020;5(1):16.

16. Bjørklund G, Aaseth J, Dos ¸a MD, et al. Does diet play a role in reducing nociception related to inflammation and chronic pain? Nutrition. 2019;66:153–65. https://doi.org/10.1016/j.nut.2019.04.007.

17. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48(4):677–85.

18. Lopez-Garcia E, Schulze MB, Fung TT, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. 2004;80:1029–35.

19. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005;135:562–6.

20. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63(2):S5-21.

21. Dragan S, Şerban MC, Damian G, Buleu F, Valcovici M, Cristodorescu R. Dietary patterns and interventions to alleviate chronic pain. Nutrients. 2020;12(9):E2510.

22. Frech TM, Clegg DO. The utility of nutraceuticals in the treatment of osteoarthritis. Curr Rheumatol Rep. 2007;9(1):25–30.

23. Walker-Bone K. “Natural remedies” in the treatment of osteoarthritis. Drugs Aging. 2003;20(7):517–26.

24. Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther. 2008;14(3):234–47.

25. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279–312.

26. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res. 2007;21(3):278–83.

27. Lin JA, Chen JH, Lee YW, et al. Biphasic effect of curcumin on morphine tolerance: a preliminary evidence from cytokine/chemokine protein array analysis. Evid Based Complement Alternat Med. 2011. https://doi.org/10.1093/ecam/neo018.

28. Marton LT, Barbalho SM, Sloan KP, et al. Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy—a systematic review. Crit Rev Food Sci Nutr. 2020;59(13):2136–43.

29. Ross J. Practical Pain Management. Amino acids and diet in chronic pain management. https://www.practicalpainmanagement.com/treatments/nutraceutical/amino-acids-diet-chronic-pain-management. Accessed 2012.

30. Baldissarro E, Aquilani R, Boschi F, et al. The hip functional retrieval after elective surgery may be enhanced by supplemented essential amino acids. Biomed Res Int. 2016;2016:9318329. https://doi.org/10.1155/2016/9318329.

31. Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol. 2011;22(5–6):390–404.

32. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.

33. Jovanovic F, Candido KD, Knezevic NN. The role of the kynurenine signalling pathway in different chronic pain conditions and potential use of therapeutic agents. Int J Mol Sci. 2020;21(17):6045.

34. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009;6(4):703–12.

35. Russell AL, McCarty MF. DL-phenylalanine markedly potentiates opiate analgesia—an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. Med Hypotheses. 2000;55(4):283–8.

36. Chen TJ, Blum K, Payte JT, et al. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses. 2004;63(3):538–48.

37. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68. https://doi.org/10.1186/1750-1172-768.
38. Maldonado C, Vázquez M, Fagiolo P. Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders. Curr Pharm Des. 2020;26(12):1277–85.

39. Di Cesare ML, Ghelardini C, Calvani M, et al. Protective effect of acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci. 2007;26(4):820–7.

40. Chiechio S, Copani A, Gereau RW, Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs. 2007;21(Suppl 1):31–8.

41. Crucchi G, Di Stefano G, Fattaposta F, et al. L-Acetyl-carnitine in patients with carpal tunnel syndrome: effects on nerve protection. Hand Funct Pain CNS Drugs. 2017;31(12):1103–11.

42. Menzies V, Starkweather A, Yao Y, et al. Exploring associations between metabolites and symptoms of fatigue, depression and pain in women with fibromyalgia. Biol Res Nurs. 2021;23(1):119–26.

43. Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci. 2011;34(11):599–609.

44. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009;89(3–4):126–30.

45. Del Giorno R, Skaper S, Paladini A, Varrassi G. Palmitoylethanolamide, a special

46. Alshelh Z, Mills EP, Kosanovic D, et al. Effects of glial modulator palmitoylethanolamide on chronic pain intensity and brain function. J Pain Res. 2019;12:2427–39.

47. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26:99–104.

48. Gugliandolo E, Barbagallo A, Peritore AF, Cuzzocrea S, Crupi R. Oral supplementation with ultramicronized palmitoylethanolamide for joint disease and lameness management in four jumping horses: a case report. Animals. 2020;10(9):1469.

49. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special
food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11–24.

62. Medina Cruz D, Mi G, Webster TJ. Synthesis and characterization of biogenic selenium nanoparticles with antimicrobial properties made by Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli and Pseudomonas aeruginosa. J Biomed Mater Res A. 2018;106(5):1400–12. https://doi.org/10.1002/jbm.a.36347.

63. Kieliszek M, Lipinski B, Blażejak S. Application of sodium selenite in the prevention and treatment of cancers. Cells. 2017;6(4):39. https://doi.org/10.3390/cells6040039.

64. Reinhard P, Schweinsberg F, Wernet D, Kötter I. Selenium status in fibromyalgia. Toxicol Lett. 1998;96–97:177–80.

65. Yüksel E, Nazroğlu M, Şahin M, Çiğ B. Involvement of TRPM2 and TRPV1 channels on hyperalgesia, apoptosis and oxidative stress in rat fibromyalgia model: protective role of selenium. Sci Rep. 2017;7(1):17543.

66. Sousa FSS, Birmann PT, Baldinotti R, et al. α-(Phenylselanyl) acetophenone mitigates reserpine-induced pain-depression dyad: behavioral, biochemical and molecular docking evidences. Brain Res Bull. 2018;142:129–37.

67. Welch AA, Skinner J, Hickson M. Dietary magnesium may be protective for aging of bone and skeletal muscle in middle and younger older age men and women: cross-sectional findings from the UK Biobank cohort. Nutrients. 2017;9(11):1189. https://doi.org/10.3390/nu9111189.

68. Rondón LJ, Privat AM, Daulhac L, et al. Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain. J Physiol. 2010;588(Pt 21):4205–15. https://doi.org/10.1113/jphysiol.2010.197004.

69. Sun J, Lin H, He G, Lin W, Yang J. Magnesium sulphate attenuate remifentanil-induced postoperative hyperalgesia via regulating tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord. BMC Anesthesiol. 2017;17:30. https://doi.org/10.1186/s12871-017-0325-3.

70. Banerjee S, Jones S. Magnesium as an alternative or adjunct to opioids for migraine and chronic pain: a review for the clinical effectiveness and guidelines [Internet]. Ottawa: Canadian Agency for drugs and Technologies in Health; 2017. p. NBK475794.

71. Oh TK, Chung SH, Park J, et al. Effects of perioperative magnesium sulphate administration on postoperative chronic knee pain in patients undergoing total knee arthroplasty: a retrospective evaluation. J Clin Med. 2019;8(12):2231.

72. Park R, Ho AM-H, Pickering G, Arendt-Nielsen L, Mohiuddin M, Gilron I. Efficacy and safety of magnesium for the management of chronic pain in adults: a systematic review. Anesth Analg. 2020;131(3):76–75.

73. Tarleton EK, Kennedy AG, Rose GL, Littenberg B. Relationship between magnesium intake and chronic pain in US adults. Nutrients. 2020;12(7):2104.

74. Rausaria S, Ghaffari MM, Kamadulski A, et al. Retooling manganese(III) porphyrin-based peroxynitrite decomposition catalysts for selectivity and oral activity: a potential new strategy for treating chronic pain. J Med Chem. 2011;54(24):8658–69.

75. Li L, Yang X. The essential element manganese, oxidative stress, and metabolic diseases: links and interactions. Oxid Med Cell Longev. 2018;2018:7580707. https://doi.org/10.1155/2018/7580707.

76. Ang CD, Alviar MJM, Dans AL, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;3:CD004573. https://doi.org/10.1002/14651858.CD004573.pub3.

77. Kuhlwein A, Meyer HJ, Koehler CO. Reduced diclofenac administration by B vitamins: results of a randomized double-blind study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebral syndromes. Klin Wochenschr. 1990;68(2):107–15.

78. Reyes-García G, Medina-Santillán R, Terán-Rosas F, Mateos-García E, Castillo-Henkel C. Characterization of the potentiation of the antinociceptive effect of diclofenac by vitamin B complex in the rat. J Pharmacol Toxicol Methods. 2004;47:88–91.

79. Franc¸a DS, Souza AL, Almeida KR, Dolabella SS, Martinelli C, Coelho MM. B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. Eur J Pharmacol. 2001;421(3):157–64.

△ Adis
82. Yu CZ, Liu YP, Liu S, Yan M, Hu SJ, Song XJ. Systematic administration of B vitamins attenuates neuropathic hyperalgesia and reduces spinal neuron injury following temporary spinal cord ischaemia in rats. Eur J Pain. 2014;18(1):76–85. https://doi.org/10.1002/j.1532-2149.2013.00390.x.

83. Kopruszinski CM, Reis RC, Bressan E, Reeh PW, Chichorro JG. Vitamin B complex attenuated heat hyperalgesia following infraorbital nerve constriction in rats and reduced capsaicin in vivo and in vitro effects. Eur J Pharmacol. 2015;762:326–32.

84. Jhun J, Min HK, Na HS, et al. Combination treatment with Lactobacillus acidophilus LA-1, vitamin B, and curcumin ameliorates the progression of osteoarthritis by inhibiting the pro-inflammatory mediators. Immunol Lett. 2020;228:112–21.

85. Das UN. Exploring the actions of vitamin C. CMAJ. 2001;165(1):13–4.

86. Fain O. Musculoskeletal manifestations of scurvy. Jt Bone Spine. 2005;72(2):124–8.

87. Dionne CE, Laurin D, Desrosiers T, et al. Serum vitamin C and spinal pain: a nationwide study. Pain. 2016;157(11):2527–35.

88. Ekrol I, Duckworth AD, Ralston SH, Court-Brown CM, McQueen MM. The influence of vitamin C on the outcome of distal radial fractures: a double-blind, randomized controlled trial. J Bone Jt Surg Am. 2014;96(17):1451–9.

89. Kim MS, Kim DJ, Na CH, Shin BS. A study of intravenous administration of vitamin C in the treatment of acute herpetic pain and postherpetic neuralgia. Ann Dermatol. 2016;28(6):677–83.

90. Carr AC, Vissers MCM, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014;4(283):1–7.

91. Zeraati F, Araghi-Chian M, Farjoo MH. Ascorbic acid interaction with analgesic effect of morphine and tramadol in mice. Anesthesiol Pain Med. 2014;4(3):e19529.

92. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189.

93. Carr AC, McCall C. The role of vitamin C in the treatment of pain: new insights. J Transl Med. 2017;15:77. https://doi.org/10.1186/s12967-017-1179-7.

94. US Department of Health and Human Services. National institutes of health/office of dietary supplements. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#h3. Accessed 2020.

95. Jansen JA, Haddad FS. High prevalence of vitamin D deficiency in elderly patients with advanced osteoarthritis scheduled for total knee replacement associated with poorer preoperative functional state. Ann R Coll Surg Engl. 2013;95(8):569–72.

96. Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am. 2010;39(2):321–31.

97. McCarthy EK, Kiely M. Vitamin D and muscle strength throughout the life course: a review of epidemiological and intervention studies. J Hum Nutr Diet. 2015;28(6):636–45.

98. Shinchuk L, Holick M. Vitamin D and rehabilitation: improving functional outcomes. Nutr Clin Pract. 2007;22(3):297–304.

99. Matossian-Motley DL, Drake DA, Samimi JS, Camargo CA Jr, Quraishi SA. Association between serum 25(OH)D level and nonspecific musculoskeletal pain in acute rehabilitation unit patients. JPEN J Parenter Enteral Nutr. 2016;40(3):367–73.

100. Shipton EE, Shipton EA. Vitamin D deficiency and pain: clinical evidence of low levels of vitamin D and supplementation in chronic pain states. Pain Ther. 2015;4:67–87.

101. Waikakul S. Serum 25-hydroxy-calciferol level and failed back surgery syndrome. J Orthop Surg (Hong Kong). 2012;20(1):18–22.

102. Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med. 2008;168(7):771–2.

103. Jesus CA, Feder D, Peres MF. The role of vitamin D in pathophysiology and treatment of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):355. https://doi.org/10.1007/s11916-013-0355-6.

104. Laslett LL, Quinn S, Burgess JR, et al. Moderate vitamin D deficiency is associated with changes in knee and hip pain in older adults: a 5-year longitudinal study. Ann Rheum Dis. 2014;73(4):697–703.

105. Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5):745–7.

106. Huang W, Shah S, Long Q, Crankshaw AK, Tangpricha V. Improvement of pain, sleep, and quality of life in chronic pain patients with vitamin D supplementation. Clin J Pain. 2013;29(4):341–7.
107. Wepner F, Scheuer R, Schuetz-Wieser B, et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain. 2014;155:261–8.

108. Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: a systematic review and meta-analysis of randomized clinical trials. Clin Biochem. 2017;50(18):1312–6.

109. McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA. 2013;309(2):155–62.

110. Helde-Frankling M, Höijer J, Bergqvist J, Björkhem-Bergman L. Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections—results from a matched case-control study. PLoS One. 2017;12(8):e0184208. https://doi.org/10.1371/journal.pone.0184208.

111. Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2007;10(1):12–9.

112. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13(3):100–5.

113. Helde-Frankling M, Björkhem-Bergman L. Vitamin D in pain management. Int J Mol Sci. 2017;18:2170. https://doi.org/10.3390/ijms18102170.

114. Cury Y, Picolo G, Gutierrez VP, Ferreira SH. Pain and analgesia: the dual effect of nitric oxide in the nociceptive system. Nitric Oxide. 2011;25(3):243–54.

115. Ambrożewicz E, Muszyńska M, Tokajuk G, Gryniewicz G, Żarković N, Skrzydłowska E. Beneficial effects of vitamins K and D3 on redox balance of human osteoblasts cultured with hydroxyapatite-based biomaterials. Cells. 2019;8(4):325. https://doi.org/10.3390/cells8040325.

116. Lanham-New SA. Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment. Proc Nutr Soc. 2008;67(2):163–76. https://doi.org/10.1017/S0029665108007003.

117. Packer L. Protective role of vitamin E in biological systems. Am J Clin Nutr. 1991;53(4 Suppl):1058S–1055S.

118. Edmondsa SE, Winyarda PG, Guoa R, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis. 1997;56(11):649–55.

119. Blankenhorn G. Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double blind study. Z Orthop Ihre Grenzgeb. 1986;124(3):340–3.

120. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhea. BJOG Int J Obstetr Gynaecol. 2005;112:466–9. https://doi.org/10.1111/j.1471-0528.2004.00495.x.

121. Shohel F, Jenabi E. The effects of vitamin E on muscular pain reduction in students affected by premenstrual syndrome. Iran J Obstet Gynecol Infertil. 2014;17(96):1–5.

122. Argyriou A, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manag. 2006;32(3):237–44.

123. Wadleigh R, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med. 1992;92(5):481–4.

124. Kim HK, Kim JH, Gao X, et al. Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain. Pain. 2006;122(1–2):53–62.

125. Kiecolt-Glaser JK. Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge. Psychosom Med. 2010;72(4):365–9.

126. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.

127. De Feo M, Paladini A, Ferri C, et al. Anti-inflammatory and anti-nociceptive effects of cocoa: a review on future perspectives in treatment of pain. Pain Therapy. 2020;9:231–40.

128. Kuwahara A, Matsuda K, Kuwahara Y, Asano S, Inui T, Marunaka Y. Microbiota-gut-brain axis: enteroendocrine cells and the enteric nervous system form an interface between the microbiota and the central nervous system. Biomed Res. 2020;31(5):199–216.

129. Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth. 2019;123(5):637–54.

130. Russo R, Cristiano C, Avagliano C, et al. Gut-brain axis: role of lipids in the regulation of inflammation, pain and CNS diseases. Curr Med Chem. 2018;25(32):3930–52.

131. Kaptchuk TJ, Hemond CC, Miller FG. Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ. 2020;370:m1668.